ZeClinics is a Contract Research Organisation that provides pre-clinical testing services using the zebrafish model. ZeClinics expertise in CRISPR genome editing allows developing custom zebrafish genetic models to mimic human disease and addressing the biomedical relevance of candidate compounds and genes in vivo. Zebrafish bridges the gap between cell and rodent experimental models, enabling accelerated and cost-effective drug and target discovery. Our services are tailored for Biotech, Pharma, Agrochemical, Food, and Cosmetic companies and are classified in the following platforms:

- ZeEfficacy platform: portfolio of ready-to-use zebrafish models of disease for drug discovery and genetic functional studies in central nervous system, ophthalmology, metabolic areas among other.

- ZeTox platform: portfolio of in vivo general and organ-specific toxicity testing services for environmental safety and human risk assessment.

- ZeGenesis platform: the most up-to-date genetic catalog for highly efficient mutagenesis, transgenesis, and gene expression modulation to generate zebrafish models of human disease. ZeClinics is a CRISPR/Cas9-licensed organization with extensive experience in generating knock-out and transgenic lines.